Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | TGM2 | P21980 | 2/20 | 0.44 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119871 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2ITGA4ITGB7 | |
| SCHEMBL6499392 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2ITGA4ITGB7 | |
| SCHEMBL29679135 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2ITGA4ITGB7 | |
| SCHEMBL6506341 | 0.91 | SIRT2 (0.45) | MDM4TP53MDM2ITGA4ITGB7 | |
| SCHEMBL6506337 | 0.91 | SIRT2 (0.45) | MDM4TP53MDM2ITGA4ITGB7 | |
| SCHEMBL31369447 | 0.89 | MDM4 (0.49) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL25356318 | 0.89 | MDM4 (0.49) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL31210307 | 0.89 | MDM4 (0.49) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL30229488 | 0.89 | MDM4 (0.49) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL25356314 | 0.89 | MDM4 (0.49) | MDM4TP53MDM2CASP3SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300180-A1 | Growth Hormone Secretagogue Receptor 1A Ligands | GASTROTECH PHARMA A/S (DK) | 2008-12-04 | — | — | US | disclosed |
| US-20080300180-A1 | Growth Hormone Secretagogue Receptor 1A Ligands | GASTROTECH PHARMA A/S (DK) | 2008-12-04 | — | — | US | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300180-A1 | Growth Hormone Secretagogue Receptor 1A Ligands | GHSR, GHRHR, GIPR | MDM4 4461/4885TP53 1532/4885MDM2 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.